http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Original Article : Effect of Biofeedback Therapy in Constipation According to Rectal Sensation
( Ji Yong Ahn ),( Seung Jae Myung ),( Kee Wook Jung ),( Dong Hoon Yang ),( Hyun Sook Koo ),( So Young Seo ),( In Ja Yoon ),( Kyung Jo Kim ),( Byong Duk Ye ),( Jeong Sik Byeon ),( Hwoon Yong Jung ),( S 대한간학회 2013 Gut and Liver Vol.7 No.2
Background/Aims: The pathophysiologic mechanism of rectal hyposensitivity (RH) is not well documented, and the significance of RH in biofeedback therapy (BFT) has not been evaluated. Thus, we aimed to assess the effect of BFT in constipated patients according to the presence of RH. Methods: Five hundred and ninety constipated patients (238 males and 352 females) underwent anorectal physiologic assessments. Of these, anorectal manometry was performed before and after BFT in 244 patients (63 RH and 181 non-RH patients). Results: The success rate of BFT was 56% in the RH and 61% in the non-RH group (p=0.604). The measurements of resting pressure, squeezing pressure, desire to defecate volume, urge to defecate volume, and maximum volume were decreased after BFT in the RH group (p<0.05), whereas only resting and squeezing pressures were decreased in the non-RH group (p<0.05). Among the RH group, individuals who responded to BFT showed decreased resting pressure, squeezing pressure, desire to defecate, urge to defecate, and maximum volume and increased balloon expulsion rate; among those who did not respond to BFT, only desire to defecate volume was improved. Conclusions: In constipated patients with RH, changes of anorectal manometric findings differed in comparison to patients without RH. The responses to BFT showed both anorectal muscle relaxation and restoration of rectal sensation. (Gut Liver 2013;7:157-162)
변지용(Byeon, Ji Yong),이미경(Lee, Mi Kyung),정재연(Chung, Jae Youn),유사무엘(Yoo, Samuel),전용관(Jeon, Justin Y.) 대한종양간호학회 2019 Asian Oncology Nursing Vol.19 No.2
Purpose: The purpose of this study was to investigate the exercise participation experiences of colorectal cancer survivors. Methods: A phenomenological method was used in this study. Ten adult colorectal cancer survivors were recruited and data were collected through in-depth interviews. Results: The factors involved in the experiences of colorectal cancer survivors’ exercise participation were categorized into 3 parts: (1) mental depression and isolation due to physical change, (2) barriers of exercise, (3) exercise participation for recovery. Though participants were aware of their changed body after cancer treatment and faced difficulties participating in exercise, they want to overcome these challenges through exercise participation. Conclusion: The results of this study show the exercise participation experiences of colorectal cancer survivors. Based on these findings, exercise maintenance can be promoted more effectively, and a higher exercise adherence of colorectal cancer survivors can be achieved.
Neuromuscular Characteristics and Physical Function in Participants with Parkinson’s Disease
( Ji-young Kim ),( Ji-Yong Byeon ),( Hyuk-in Yang ),( Jeonghoon-Oh ),( Ju-hee Lee ),( Moon-Ki Choi ),( Hae-Dong Lee ),( Justin Y Jeon ) 한국운동생리학회 2021 운동과학 Vol.30 No.3
PURPOSE: This study aimed to investigate the level of physical function, lower body strength, and muscle activation during various types of muscle contraction in participants with and without Parkinson’s disease (PD). METHODS: Twelve participants with PD (mean age=63.17±6.24 years) and 12 age- and sex-matched healthy adults (mean age = 58.67±6.39 years) were recruited. An isokinetic dynamometer was used to measure the length- and velocity-dependent maximum voluntary force and the rate of torque development (RTD) of the knee extensor muscles. Muscle activation of the vastus lateralis (VL), vastus medialis (VM), and rectus femoris (RF) muscles of both legs was examined using surface electromyography. The 6-minute walk test, chair stand test, timed up-and-go test, sit-and-reach test, and back-scratch test were performed to assess physical function. RESULTS: Compared to healthy individuals, participants with PD showed significantly lower maximum voluntary force and RTD (p<.05), performed fewer repetitions in the chair stand test (11.64±1.75 vs. 17.08±2.27, p<.001), were slower in the timed up-and-go test (8.36±1.42 vs. 5.65±1.07, p<.001), and walked shorter distances in the 6-minute walk test (424.17±65.97 vs. 539.47±63.18, p<.001). However, activation of the three different muscles during isometric and isokinetic muscle contraction was not different between participants with and without PD. CONCLUSIONS: Preserved muscle activation and significantly lower muscle strength during various types of muscle contractions may suggest lower muscle strength and efficiency. The lower physical function seen in participants with mild PD could be due to disease and low physical activity-related muscle atrophy rather than lower muscle activation.
Byeon, Sung Yong,Kim, Ji Han,Lee, Jun Yeob American Chemical Society 2017 ACS APPLIED MATERIALS & INTERFACES Vol.9 No.15
<P>CN-modified host materials, 9-(2-(9-pheuyl-9H-carbazol-3-yl)pheny1)-9H-carbazole-3-carbonitrile (o-CzCN) and 9-(3-(9-phenyl-9H-carbazol-3-yl)phenyl)-9H-carbazole-3-carbonitrile (m-CzcN)) which can, improve the external quantum efficiency and lifetime of both blue phosphorescent and thermally activated delayed fluorescent (TADF) emitters were developed. A molecular design approach to stabilize the molecular structure and reduce: the energy gap produced two high triplet energy host materials of o-CzCN and m-CzCN compatible with the phosphorescent and TADF emitters. The new host materials lowered operation voltage, increased quantum efficiency, and elongated lifetime of both phosphorescent and TADF devices.</P>
( Ji Young Yang ),( Kyung Wook Jo ),( Seok Chan Hong ),( Bin Yoo ),( Chang Keun Lee ),( Yong Gil Kim ),( Suk Kyun Yang ),( Jeong Sik Byeon ),( Kyung Jo Kim ),( Byong Duk Ye ),( Sang Hyoung Park ),( Ta 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Tumor necrosis factor antagonists are increasingly used to treat patients with immune-mediated infi ammatory disease including rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, and ulcerative colitis. Because TNF-alpha is essential for the prevention of latent tuberculosis recrudescence, patients treated with TNF-alpha inhibitors are at increased risk of developing active TB. The time of initiating anti-TNF therapy following the induction of LTBI treatment is different depending on each nation`s guideline. We aimed to investigate the treatment outcome of patients with immune-mediated infi ammatory disease who received anti-tumor necrosis factor therapy within 3 weeks of latent tuberculosis infection treatment. Methods: A total of 411 patients received LTBI treatment before commencing TNF antagonist between June 2004 and October 2013 at a tertiary referral center in South Korea. Their medical records were retrospectively reviewed. Results: The mean age of the 411 study subjects was 44.5 years and 261(63.5%) were male. The underlying IMID was ankylosing spondylitis in 203(49.4%), rheumatoid arthritisin 136(33.3%) and infi ammatory bowel diseases in 57(13.9%) patients. Anti-TNF agent was initiated in 61 patients(14.8%) within 3 weeks after chemoprophylaxis for LTBI, whereas 3 weeks later in remaining 350 patients(85.2%). These two groups were comparable in terms of baseline characteristics, treatment regimens, anti-TNF agents used and follow-up duration except signifi cant difference of the mean duration of LTBI treatment before starting anti-TNF therapy(8 vs. 30 days, p < 0.001). A total of 6 patients developed TB during follow-up period. All of these patients received anti-TNF agents 3 weeks after initiation of LTBI treatment. None in the patients who commenced TNF antagonist within 3 weeks of LTBI treatment developed TB. Conclusions: The present study suggested that TNF antagonist may be initiated within 3 weeks of LTBI treatment in patients with IMID.
Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites
Byeon, Ji-Yeong,Kim, Young-Hoon,Na, Han-Sung,Jang, Jong-Hwa,Kim, Se-Hyung,Lee, Yun-Jeong,Bae, Jung-Woo,Kim, In Su,Jang, Choon-Gon,Chung, Myeon-Woo,Lee, Seok-Yong Springer-Verlag 2015 Archives of Pharmacal Research Vol.38 No.11
( Ji Young Yang ),( Kyung Wook Jo ),( Seok Chan Hong ),( Bin Yoo ),( Chang Keun Lee ),( Yong Gil Kim ),( Suk Kyun Yang ),( Jeong Sik Byeon ),( Kyung Jo Kim ),( Byong Duk Ye ),( Sang Hyoung Park ),( Ta 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: Tumor necrosis factor antagonists are increasingly used to treat patients with immune-mediated inflammatory disease including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Because TNF-alpha is essential for the prevention of latent tuberculosis recrudescence, patients treated with TNF-alpha inhibitors are at increased risk of developing active TB. The time of initiating anti-TNF therapy following the induction of LTBI treatment is different depending on each nation’s guideline. We aimed to investigate the treatment outcome of patients with immune-mediated inflammatory disease who received anti- tumor necrosis factor therapy within 3 weeks of latent tuberculosis infection treatment. Methods: A total of 411 patients received LTBI treatment before commencing TNF antagonist between June 2004 and October 2013 at a tertiary referral center in South Korea. Their medical records were retrospectively reviewed. Results: The mean age of the 411 study subjects was 44.5 years and 261(63.5%) were male. The underlying IMID was ankylosing spondylitis in 203(49.4%), rheumatoid arthritis in 136(33.3%) and inflammatory bowel diseases in 57(13.9%) patients. Anti-TNF agent was initiated in 61 patients(14.8%) within 3 weeks after chemoprophylaxis for LTBI, whereas 3 weeks later in remaining 350 patients( 85.2%). These two groups were comparable in terms of baseline characteristics, treatment regimens, anti-TNF agents used and follow-up duration except significant difference of the mean duration of LTBI treatment before starting anti-TNF therapy(8 vs. 30 days, p < 0.001). A total of 6 patients developed TB during follow-up period. All of these patients received anti-TNF agents 3 weeks after initiation of LTBI treatment. None in the patients who commenced TNF antagonist within 3 weeks of LTBI treatment developed TB. Conclusions: The present study suggested that TNF antagonist may be initiated within 3 weeks of LTBI treatment in patients with IMID.
( Yong-wook Kim ),( Seung-yeon Jo ),( Yeoung-in Byeon ),( Ji-ho Kwon ),( Seok-hee Im ),( Su-hyeon Cheon ),( Eun-joo Kim ) 대한물리의학회 2019 대한물리의학회지 Vol.14 No.1
PURPOSE: This study examined the dynamic range of motion (ROM) of the hip, knee, and ankle joint when wearing different shoe sole lifts, as well as the limb asymmetry of the range according to the leg length discrepancy (LLD) during normal speed walking. METHODS: The participants were 40 healthy adults. A motion analysis system was used to collect kinematic ROM data. The participants had 40 markers attached to their lower extremities and were asked to walk on a 6 m walkway, under three different shoe lift conditions (without an insole, 1 cm insole, and 2 cm insole). Visual3D professional software was used to coordinate kinematic ROM data. RESULTS: Most of the ROM variables of the short limbs were similar under each insole lift condition (p>.05). In contrast, when wearing a shoe with a 2 cm insole lift, the long limbs showed significant increases in flexion and extension of the knee joint as well as; plantarflexion, dorsiflexion, pronation, eversion, and inversion of the ankle joint (p<.05). Of the shoes with the insole lifts, significant differences in all ROM variables were observed between the left and right knees, except for the knee internal rotation (p<.05). CONCLUSION: As the insole lift was increased, more ROM differences were observed between the left and right limbs, and the asymmetry of the bilateral lower limbs increased. Therefore, appropriate interventions for LLD are needed because an artificial mild LLD of less than 2.0 cm could lead to a range of musculoskeletal problems of the lower extremities, such as knee and ankle osteoarthritis.
Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine
Ji-Yeong Byeon,이충민,Yea-Jin Lee,Young-Hoon Kim,Se-Hyung Kim,정의현,Won Ki Chae,Yun Jeong Lee,Choon-Gon Jang,Seok Yong Lee 대한약학회 2019 Archives of Pharmacal Research Vol.42 No.2
Tolterodine is metabolized to an active 5-hydroxymethyl tolterodine (5-HMT) by CYP2D6. This study investigated the relationship between CYP2D6 genotypes and pharmacokinetics of tolterodine and its active metabolite in healthy Korean subjects. All volunteers were genotyped for CYP2D6 and divided into four different genotype groups (CYP2D6*wt/*wt [*wt = *1 or *2], CYP2D6*wt/*10, CYP2D6*10/*10, and CYP2D6*5/*10). Each subject received a single oral dose of tolterodine tartrate (2 mg) in single-dose phase of the study. After the single-dose phase of the study, the same subjects received a single oral dose of tolterodine tartrate (2 mg) once daily for 1 week during multiple-dose tolterodine administration phase. Plasma concentrations of tolterodine and 5-HMT were measured by using liquid chromatography-tandem mass spectrometry method. Our study demonstrated that plasma exposure of tolterodine in CYP2D6*10/*10 and CYP2D6*5/*10 group significantly increased, compared with CYP2D6*wt/*wt group (P < 0.001). The pharmacokinetic parameters of 5-HMT were not significantly different in relation to CYP2D6 genotype, as 5-HMT itself is also metabolized by CYP2D6. With regard to active moiety (tolterodine + 5-HMT), Cmax and AUC0–24 was significantly increased in CYP2D6*10/*10 group, compared with CYP2D6*wt/*wt group (P < 0.001). Thus, our study showed the pharmacokinetics of tolterodine and its active moiety was significantly different in relation to CYP2D6 genotype.